Commercial Channels

Catherine Humphries sheds light on three key market access challenges within the ophthalmology biosimilars space.

By 2024 oncology therapeutic sales will hit $250 billion worldwide, and there will be more than 22 million cancer survivors. But commercializing how these critical therapies come to market to help patients hasn’t changed much in the past 20 years. The industry must do more, write Anne Marie Robertson and Ellen Cappellino

Leaders from Janssen, Novartis Gene Therapies, Pierre Fabre, and the German cancer app start-up Mika discuss how they are leveraging data in innovative ways to advance their engagement with the scientific community and their overall commercial operations

What does digital innovation actually mean and how is it changing the way that pharma is interacting with HCPs and patients?

An interview with Matthew Aubin of Sonexus™ Access & Patient Support.

Sandra Anderson outlines what manufacturers need to know about the regulatory environment and commercialization solutions for the Canadian market.

The benefits of establishing an in-depth go-to-market commercialization strategy for a new CGT in the beginning of clinical trials

Taking cues from launches so far in oncology and rheumatology, three important considerations for biosimilar marketability are outlined

Focusing on key groups will drive the greatest impact in health outcomes

The biggest areas of adjustment in patient support brought on by changes in consumer and physician behavior

AI-driven strategies for pharma brand marketing teams to help bridge the gap from data intelligence to execution

How to best plan out and implement a marketing data hub as a key tool to harnessing today’s omnichannel transformation in pharma

Outlining the key digital trends accelerated by the transformed healthcare landscape in 2021—and their impact on pharma commercialization strategies going forward

How the development of more quantitative and qualitative data around the patient can drive better-informed care decisions—and help avoid potential overstock scenarios that can deplete earnings

How pharma’s retooling of its promotional efforts in the post-pandemic era impacts sizing and targeting, two crucial foundational pieces to successful commercialization

Arthrex to receive US rights to distribute and commercialize Celularity’s placental-derived biomaterial products for orthopedics and sports medicine

A conversation with Vin Colicchio, vice president, supply chain and external manufacturing, Dr. Reddy’s Laboratories

A well-oiled, data-driven hub program is critical for stakeholders in supporting patients—and clearing a successful path for specialty therapies

A conversation with Cathy Traz, global advocacy head at Bristol Myers Squibb

Covid-19 reveals how important field reps will be to driving digital adoption

Embracing AI 2.0 and modern machine learning as foundational tools to deepening HCP engagement

Using technology to enable processes, drive cost savings, and deliver better patient outcomes

Are regulations hindering pharma innovations?

Five ways to adapt manufacturer-sponsored programs

Embracing digital channels and patient-centric strategies has been critical for commercial teams; a review of what some companies have done right

It marks the first time that two accrediting organizations with deeming authority from CMS have merged

Plan is to expand capabilities across the drug commercialization process

EnlivenHealth, formerly Population Health Solutions, targets better patient outcomes through advanced technology

'Contextual' AI blends human expertise and computer power

A modularized approach will enable pharma marketers to grow patient starts and improve adherence